Vern Norviel Joins Luventix Advisory Board
Luventix, a leading innovator in Intelligent Disease Diagnostics, is excited to announce that Vern Norviel has joined its Advisory Board.
Mr. Norviel, a senior partner at Wilson Sonsini Goodrich & Rosati, is a renowned expert in intellectual property law, with a focus on life sciences and medical technologies. With decades of experience advising startups and global enterprises, Mr. Norviel has guided numerous companies through strategic growth, intellectual property development, and regulatory landscapes. His deep understanding of innovation and strategic counsel will be a tremendous asset to Luventix as it continues to advance transformative solutions.
"We are delighted to welcome Vern Norviel to our Advisory Board," said George Holmes, CEO of Luventix. "His unparalleled expertise in intellectual property, his strategic insights and industry relationships will play a critical role in driving our innovation and protecting our advancements."
About Luventix
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) modeling techniques, Luventix has the unique ability to analyze data and pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment and enabling companion diagnostics as an integral endpoint.
With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions. For more information, please visit www.luventix.com
Media Contact:
